• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMC
Click for more information
0.00% 7.5¢

IMMURON LIMITED - Announcements

Market Cap $21.88M  ! watchlist Created with Sketch. Add to my watchlist

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and... Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
IMC Appendix 4E Preliminary Final Report and Statutory AccountsPRICE SENSITIVE29/08/14
IMC Paladin Labs Announces the Launch of Travelan in CanadaPRICE SENSITIVE06/08/14
IMC Immuron FY2014 Travelan Sales Exceed $1mPRICE SENSITIVE07/07/14
IMCImmuron Signs Agreement to Sell Travelan in South KoreaPRICE SENSITIVE21/05/14
IMCImmuron Extinguishes Paladin DebtPRICE SENSITIVE05/05/14
IMCAppendix 4D and Interim Financial Report - Dec 2013PRICE SENSITIVE28/02/14
IMCRenounceable Rights Issue - Closure, Acceptances & ShortfallPRICE SENSITIVE26/02/14
IMCImmuron to Raise $9.66M via Fully Underwritten Rights IssuePRICE SENSITIVE22/01/14
IMCTrading HaltPRICE SENSITIVE20/01/14
IMCImmuron's Travelan Approved for Marketing in CanadaPRICE SENSITIVE13/11/13
IMCUS FDA Clears Another IND for Phase 2 Trial for IMM-124EPRICE SENSITIVE08/11/13
IMCImmuron Allowed Travelan Patent in the United StatesPRICE SENSITIVE23/10/13
IMCAppendix 4E - Preliminary Final ReportPRICE SENSITIVE30/08/13
IMCImmuron to Adopt a New Direct-to-Wholesalers Sales ModelPRICE SENSITIVE04/06/13
IMCProspectus -Underwritten Renounceable Rights IssuePRICE SENSITIVE27/03/13
IMCFully Underwritten Renounceable Rights IssuePRICE SENSITIVE27/03/13
IMCTrading HaltPRICE SENSITIVE25/03/13
IMCFurther Positive Results on Clostridium Difficile ProgramPRICE SENSITIVE04/03/13
IMCHalf Year Results and Accounts 31 December 2012PRICE SENSITIVE28/02/13
IMCResignation of Joe Baini as Director and CEO.PRICE SENSITIVE22/02/13
IMCCLOSTRIDIUM DIFFICILE Project UpdatePRICE SENSITIVE17/12/12
IMCPositive Results from Colostridium Difficile ProgramPRICE SENSITIVE19/09/12
IMCTravelan Distribution Agreement for China and TaiwanPRICE SENSITIVE12/09/12
IMCResults for Announcement to the MarketPRICE SENSITIVE31/08/12
IMCInfluenza program for Swine FluPRICE SENSITIVE15/08/12
IMCNIH Grant for Immuron's IMM 124E for Alcholic Fatty LiverPRICE SENSITIVE06/08/12
IMCProspectus for Bonus Issue of OptionsPRICE SENSITIVE09/07/12
IMCFinalisation of Share Purchase PlanPRICE SENSITIVE18/06/12
IMCTravelan application - CanadaPRICE SENSITIVE04/06/12
IMCTravelan Distribution in Singapore, Malaysia and BruneiPRICE SENSITIVE14/05/12
IMCTravelan licensed to Thailand, Hong Kong, Cambodia, VietnamPRICE SENSITIVE10/05/12
IMCAgreement with Synlait Milk for Hyperimmune requirementsPRICE SENSITIVE07/05/12
IMCCapital Raising announcementPRICE SENSITIVE23/04/12
IMCReinstatement to Official QuotationPRICE SENSITIVE23/04/12
IMCSuspension from Official QuotationPRICE SENSITIVE20/04/12
IMCTrading Halt RequestPRICE SENSITIVE18/04/12
IMCTrading HaltPRICE SENSITIVE18/04/12
IMCImmuron appoints Joe Baini Chief Executive OfficerPRICE SENSITIVE05/03/12
IMCHalf Yearly Report and AccountsPRICE SENSITIVE28/02/12
IMCImmuron and Monash University to Collaborate on C. difficilePRICE SENSITIVE31/01/12
IMCImmuron finalises funding facilityPRICE SENSITIVE16/01/12
IMCIND cleared for NASH/Fatty Liver Phase IIb trialsPRICE SENSITIVE10/01/12
IMCResearch agreement with Harvard Medical SchoolPRICE SENSITIVE16/12/11
IMCTravelan Licence Deal with Paladin Labs Inc. CanadaPRICE SENSITIVE29/11/11
IMCImmuron submits NASH IND Application with FDAPRICE SENSITIVE07/11/11
IMCNon-Renounceable Issue ShortfallPRICE SENSITIVE04/11/11
IMCOffer Document for Non-Renounceable Rights IssuePRICE SENSITIVE31/08/11
IMCResults for Announcement to the MarketPRICE SENSITIVE31/08/11
IMCImmuron's Novel Influenza Product Advances to Human TrialPRICE SENSITIVE29/08/11
IMCPhase 2B NASH trial on track following meeting with FDAPRICE SENSITIVE22/08/11
IMCNotice of Non-Renounceable Rights IssuePRICE SENSITIVE17/08/11
IMCTravelan discovered to affect E.coli O104 outbreak in EuropePRICE SENSITIVE26/07/11
IMCHIV Program proceeds to Expanded Human TrialPRICE SENSITIVE21/07/11
IMCShareholder UpdatePRICE SENSITIVE01/06/11
IMCImmuron Granted FDA pre-IND Meeting re Phase 2b TrialPRICE SENSITIVE19/04/11
IMCImmurons Influenza Program Shows Effectiveness in TrialsPRICE SENSITIVE17/03/11
IMCImportant Progress in HIV Prevention ProjectPRICE SENSITIVE08/03/11
IMCImmuron Granted Key Patent for Influenza ProductPRICE SENSITIVE01/03/11
IMCHalf Yearly Report and AccountsPRICE SENSITIVE01/03/11
IMCAustralian Sales of Travelan expected to IncreasePRICE SENSITIVE24/02/11
IMCAppointment of New Chief Executive OfficerPRICE SENSITIVE17/01/11
IMCPreliminary Final ReportPRICE SENSITIVE31/08/10
IMCSuccessful Results from NASH Clinical TrialPRICE SENSITIVE23/08/10
IMCImmuron and Nycomed expand 'Travelan' into other territoriesPRICE SENSITIVE11/06/10
IMCCollaboration with Nycomed on Influenza ProductPRICE SENSITIVE21/05/10
IMCStrong Interest in Immuron NASH ProductPRICE SENSITIVE17/05/10
IMCNycomed Licenses Immuron's Travelan ProductPRICE SENSITIVE06/05/10
IMCPre-clinical Trials for Influenza Prevention ProductPRICE SENSITIVE04/05/10
IMCHIV Phase 2 trial completed. Final results expected mid yearPRICE SENSITIVE19/04/10
IMCShareholder Share Purchase PlanPRICE SENSITIVE19/04/10
IMCPhase II clinical trial for Metabolic Syndrome and NASHPRICE SENSITIVE29/03/10
IMCHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
IMCCommencement of Phase 2 Clinical Trials - Metabolic SyndromePRICE SENSITIVE16/12/09
IMCChairman and CEO presentations and Nycomed A'mentPRICE SENSITIVE23/11/09
IMCSignificant Progress in Treatment of Metabolic SyndromePRICE SENSITIVE11/11/09
IMCPreliminary Final ReportPRICE SENSITIVE31/08/09
IMCInfluenza Drug Development ProgramPRICE SENSITIVE13/08/09
IMCInfluenza Drug Development ProgramPRICE SENSITIVE11/08/09
IMCUpdate on Influenza research programPRICE SENSITIVE03/08/09
IMCGRAS status of Immuron Hyperimmune Oral Antibody formulationPRICE SENSITIVE20/04/09
IMCAgreement with Hadasit Medical CentrePRICE SENSITIVE20/04/09
IMCCommencement of Travelan sales in USAPRICE SENSITIVE25/03/09
IMCHalf Year Report Appendix 4DPRICE SENSITIVE26/02/09
IMCClinical Trial ApprovedPRICE SENSITIVE13/01/09
IMCUS Distribution Agreement and Strategic InvestmentPRICE SENSITIVE15/12/08
IMC Appendix 4E Preliminary Final Report and Statutory Accounts
29/08/14PRICE SENSITIVE
IMC Paladin Labs Announces the Launch of Travelan in Canada
06/08/14PRICE SENSITIVE
IMC Immuron FY2014 Travelan Sales Exceed $1m
07/07/14PRICE SENSITIVE
IMCImmuron Signs Agreement to Sell Travelan in South Korea
21/05/14PRICE SENSITIVE
IMCImmuron Extinguishes Paladin Debt
05/05/14PRICE SENSITIVE
IMCAppendix 4D and Interim Financial Report - Dec 2013
28/02/14PRICE SENSITIVE
IMCRenounceable Rights Issue - Closure, Acceptances & Shortfall
26/02/14PRICE SENSITIVE
IMCImmuron to Raise $9.66M via Fully Underwritten Rights Issue
22/01/14PRICE SENSITIVE
IMCTrading Halt
20/01/14PRICE SENSITIVE
IMCImmuron's Travelan Approved for Marketing in Canada
13/11/13PRICE SENSITIVE
IMCUS FDA Clears Another IND for Phase 2 Trial for IMM-124E
08/11/13PRICE SENSITIVE
IMCImmuron Allowed Travelan Patent in the United States
23/10/13PRICE SENSITIVE
IMCAppendix 4E - Preliminary Final Report
30/08/13PRICE SENSITIVE
IMCImmuron to Adopt a New Direct-to-Wholesalers Sales Model
04/06/13PRICE SENSITIVE
IMCProspectus -Underwritten Renounceable Rights Issue
27/03/13PRICE SENSITIVE
IMCFully Underwritten Renounceable Rights Issue
27/03/13PRICE SENSITIVE
IMCTrading Halt
25/03/13PRICE SENSITIVE
IMCFurther Positive Results on Clostridium Difficile Program
04/03/13PRICE SENSITIVE
IMCHalf Year Results and Accounts 31 December 2012
28/02/13PRICE SENSITIVE
IMCResignation of Joe Baini as Director and CEO.
22/02/13PRICE SENSITIVE
IMCCLOSTRIDIUM DIFFICILE Project Update
17/12/12PRICE SENSITIVE
IMCPositive Results from Colostridium Difficile Program
19/09/12PRICE SENSITIVE
IMCTravelan Distribution Agreement for China and Taiwan
12/09/12PRICE SENSITIVE
IMCResults for Announcement to the Market
31/08/12PRICE SENSITIVE
IMCInfluenza program for Swine Flu
15/08/12PRICE SENSITIVE
IMCNIH Grant for Immuron's IMM 124E for Alcholic Fatty Liver
06/08/12PRICE SENSITIVE
IMCProspectus for Bonus Issue of Options
09/07/12PRICE SENSITIVE
IMCFinalisation of Share Purchase Plan
18/06/12PRICE SENSITIVE
IMCTravelan application - Canada
04/06/12PRICE SENSITIVE
IMCTravelan Distribution in Singapore, Malaysia and Brunei
14/05/12PRICE SENSITIVE
IMCTravelan licensed to Thailand, Hong Kong, Cambodia, Vietnam
10/05/12PRICE SENSITIVE
IMCAgreement with Synlait Milk for Hyperimmune requirements
07/05/12PRICE SENSITIVE
IMCCapital Raising announcement
23/04/12PRICE SENSITIVE
IMCReinstatement to Official Quotation
23/04/12PRICE SENSITIVE
IMCSuspension from Official Quotation
20/04/12PRICE SENSITIVE
IMCTrading Halt Request
18/04/12PRICE SENSITIVE
IMCTrading Halt
18/04/12PRICE SENSITIVE
IMCImmuron appoints Joe Baini Chief Executive Officer
05/03/12PRICE SENSITIVE
IMCHalf Yearly Report and Accounts
28/02/12PRICE SENSITIVE
IMCImmuron and Monash University to Collaborate on C. difficile
31/01/12PRICE SENSITIVE
IMCImmuron finalises funding facility
16/01/12PRICE SENSITIVE
IMCIND cleared for NASH/Fatty Liver Phase IIb trials
10/01/12PRICE SENSITIVE
IMCResearch agreement with Harvard Medical School
16/12/11PRICE SENSITIVE
IMCTravelan Licence Deal with Paladin Labs Inc. Canada
29/11/11PRICE SENSITIVE
IMCImmuron submits NASH IND Application with FDA
07/11/11PRICE SENSITIVE
IMCNon-Renounceable Issue Shortfall
04/11/11PRICE SENSITIVE
IMCOffer Document for Non-Renounceable Rights Issue
31/08/11PRICE SENSITIVE
IMCResults for Announcement to the Market
31/08/11PRICE SENSITIVE
IMCImmuron's Novel Influenza Product Advances to Human Trial
29/08/11PRICE SENSITIVE
IMCPhase 2B NASH trial on track following meeting with FDA
22/08/11PRICE SENSITIVE
IMCNotice of Non-Renounceable Rights Issue
17/08/11PRICE SENSITIVE
IMCTravelan discovered to affect E.coli O104 outbreak in Europe
26/07/11PRICE SENSITIVE
IMCHIV Program proceeds to Expanded Human Trial
21/07/11PRICE SENSITIVE
IMCShareholder Update
01/06/11PRICE SENSITIVE
IMCImmuron Granted FDA pre-IND Meeting re Phase 2b Trial
19/04/11PRICE SENSITIVE
IMCImmurons Influenza Program Shows Effectiveness in Trials
17/03/11PRICE SENSITIVE
IMCImportant Progress in HIV Prevention Project
08/03/11PRICE SENSITIVE
IMCImmuron Granted Key Patent for Influenza Product
01/03/11PRICE SENSITIVE
IMCHalf Yearly Report and Accounts
01/03/11PRICE SENSITIVE
IMCAustralian Sales of Travelan expected to Increase
24/02/11PRICE SENSITIVE
IMCAppointment of New Chief Executive Officer
17/01/11PRICE SENSITIVE
IMCPreliminary Final Report
31/08/10PRICE SENSITIVE
IMCSuccessful Results from NASH Clinical Trial
23/08/10PRICE SENSITIVE
IMCImmuron and Nycomed expand 'Travelan' into other territories
11/06/10PRICE SENSITIVE
IMCCollaboration with Nycomed on Influenza Product
21/05/10PRICE SENSITIVE
IMCStrong Interest in Immuron NASH Product
17/05/10PRICE SENSITIVE
IMCNycomed Licenses Immuron's Travelan Product
06/05/10PRICE SENSITIVE
IMCPre-clinical Trials for Influenza Prevention Product
04/05/10PRICE SENSITIVE
IMCHIV Phase 2 trial completed. Final results expected mid year
19/04/10PRICE SENSITIVE
IMCShareholder Share Purchase Plan
19/04/10PRICE SENSITIVE
IMCPhase II clinical trial for Metabolic Syndrome and NASH
29/03/10PRICE SENSITIVE
IMCHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
IMCCommencement of Phase 2 Clinical Trials - Metabolic Syndrome
16/12/09PRICE SENSITIVE
IMCChairman and CEO presentations and Nycomed A'ment
23/11/09PRICE SENSITIVE
IMCSignificant Progress in Treatment of Metabolic Syndrome
11/11/09PRICE SENSITIVE
IMCPreliminary Final Report
31/08/09PRICE SENSITIVE
IMCInfluenza Drug Development Program
13/08/09PRICE SENSITIVE
IMCInfluenza Drug Development Program
11/08/09PRICE SENSITIVE
IMCUpdate on Influenza research program
03/08/09PRICE SENSITIVE
IMCGRAS status of Immuron Hyperimmune Oral Antibody formulation
20/04/09PRICE SENSITIVE
IMCAgreement with Hadasit Medical Centre
20/04/09PRICE SENSITIVE
IMCCommencement of Travelan sales in USA
25/03/09PRICE SENSITIVE
IMCHalf Year Report Appendix 4D
26/02/09PRICE SENSITIVE
IMCClinical Trial Approved
13/01/09PRICE SENSITIVE
IMCUS Distribution Agreement and Strategic Investment
15/12/08PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
7.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $21.88M
Open High Low Value Volume
7.6¢ 7.6¢ 7.5¢ $9.071K 120.6K

Buyers (Bids)

No. Vol. Price($)
1 57518 7.5¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 10000 1
View Market Depth
Last trade - 15.45pm 22/11/2024 (20 minute delay) ?
IMC (ASX) Chart

Top Stories

Sales growth pushes Lovisa's fortunes (and shares) upwards

Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
HotCopper Highlights: Your most watched stocks for Week 47, 2024 In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.